Zanubrutinib

Zanubrutinib (BGB-3111) is a selective and orally active Bruton tyrosine kinase (Btk) inhibitor (IC50: 0.3 nM) [1][2].

Product Specifications

CAS Number

[1691249-45-2]

Product Name Alternative

BGB-3111

UNSPSC

12352005

Hazard Statement

H301, H311, H331, H341

Target

Btk

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Zanubrutinib.html

Purity

99.71

Solubility

DMSO : 175 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

NC(C1=C2N(N=C1C3=CC=C(OC4=CC=CC=C4)C=C3)[C@H](C5CCN(C(C=C)=O)CC5)CCN2)=O

Molecular Formula

C27H29N5O3

Molecular Weight

471.55

Precautions

H301, H311, H331, H341

References & Citations

[1]Na Li, et al. Abstract 2597: BGB-3111 is a novel and highly selective Bruton's tyrosine kinase (BTK) inhibitor. Cancer Res 2015;75 (15 Suppl) :Abstract nr 2597.|[2]Guo Y, et al. Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase. J Med Chem. 2019 Sep 12;62 (17) :7923-7940.